https://www.selleckchem.com/pr....oducts/PHA-793887.ht
05). Receiver operating characteristic (ROC) analysis showed that CZP concentrations ≥28.0 μg/mL at Week 12, and ≥17.6 μg/mL at Week 24, were associated with a greater likelihood of achieving LDA/remission outcomes. Although confirmatory studies are warranted to define the optimal CZP therapeutic range at Weeks 12 and 24, these data indicate that CZP concentrations may be associated with improvement of disease activity. © 2020 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of the Americ